Cargando…

Safe use of proton pump inhibitors in patients with cirrhosis

AIMS: Proton pump inhibitors (PPIs) belong to the most frequently used drugs, also in patients with cirrhosis. PPIs are extensively metabolized by the liver, but practice guidance on prescribing in cirrhosis is lacking. We aim to develop practical guidance on the safe use of PPIs in patients with ci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weersink, Rianne A., Bouma, Margriet, Burger, David M., Drenth, Joost P.H., Harkes‐Idzinga, S. Froukje, Hunfeld, Nicole G.M., Metselaar, Herold J., Monster‐Simons, Margje H., van Putten, Sandra A.W., Taxis, Katja, Borgsteede, Sander D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046475/ https://www.ncbi.nlm.nih.gov/pubmed/29688583 http://dx.doi.org/10.1111/bcp.13615

Ejemplares similares

Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis
por: Weersink, Rianne A., et al.
Publicado: (2018)

Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion
por: Weersink, Rianne A, et al.
Publicado: (2016)

Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment
por: Weersink, Rianne A., et al.
Publicado: (2019)

Guidance for Safety and Dosing of Medicines in Patients With Cirrhosis Is Available
por: Weersink, Rianne A., et al.
Publicado: (2019)

Prevalence of Drug Prescriptions and Potential Safety in Patients with Cirrhosis: A Retrospective Real-World Study
por: Weersink, Rianne A., et al.
Publicado: (2018)

Why zolpidem increases the risk of falls and fractures in patients with cirrhosis
por: Weersink, Rianne Antoinet, et al.
Publicado: (2022)

Medication safety in patients with hepatic impairment: A survey of community pharmacists' knowledge level and their practice in caring for these patients
por: Weersink, Rianne A., et al.
Publicado: (2020)

Medication-Related Problems in Liver Transplant Recipients in the Outpatient Setting: A Dutch Cohort Study
por: Mulder, Midas B., et al.
Publicado: (2021)

Evaluation of medication-related problems in liver transplant recipients with and without an outpatient medication consultation by a clinical pharmacist: a cohort study
por: Mulder, Midas B., et al.
Publicado: (2022)

A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe
por: Koomen, Jeroen V., et al.
Publicado: (2021)

The Development of Practice Recommendations for Drug-Disease Interactions by Literature Review and Expert Opinion
por: van Tongeren, Justine M. Z., et al.
Publicado: (2020)

NAFLD Phenotype in Patients With V-ATPase Proton Pump Assembly Defects
por: Jansen, Jos C., et al.
Publicado: (2018)

Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008
por: Kuiper, Edith MM, et al.
Publicado: (2010)

Improving Medication‐Related Outcomes in Chronic Liver Disease
por: Hayward, Kelly L., et al.
Publicado: (2020)

Collaboration Is Needed to Translate Pharmacology Data Into Better Health Outcomes in Chronic Liver Disease
por: Weersink, Rianne A., et al.
Publicado: (2021)

Preventing dispensing errors by alerting for drug confusions in the pharmacy information system—A survey of users
por: Campmans, Zizi, et al.
Publicado: (2018)

Standard MRI May Not Predict Specific Acute Anterior Cruciate Ligament Rupture Characteristics
por: Hoogeslag, Roy A.G., et al.
Publicado: (2021)

Treatment of refractory ascites with an automated low‐flow ascites pump in patients with cirrhosis
por: Stirnimann, G., et al.
Publicado: (2017)

Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis
por: De Roza, Marianne Anastasia, et al.
Publicado: (2019)

Proton pump inhibitor use is associated with a variety of infections in patients with liver cirrhosis
por: Labenz, Christian, et al.
Publicado: (2020)

Concomitant Intake of Coca‐Cola to Manage the Drug–Drug Interaction Between Velpatasvir and Omeprazole Studied in Healthy Volunteers
por: van Seyen, Minou, et al.
Publicado: (2019)

Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial
por: Chrispijn, Melissa, et al.
Publicado: (2011)

A new noninvasive technique for estimating hepatic triglyceride: will liver biopsy become redundant in diagnosing non-alcoholic fatty liver disease?
por: Betzel, Bark, et al.
Publicado: (2014)

A cost–benefit analysis of hospital-wide medication reviews: a period prevalence study
por: Wilkes, Sarah, et al.
Publicado: (2021)

Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis
por: Horvath, Angela, et al.
Publicado: (2019)

Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis
por: Kuan, Yi-Chun, et al.
Publicado: (2019)

Proton pump inhibitor use and mortality in patients with cirrhosis: a meta-analysis of cohort studies
por: Wu, Xiaoli, et al.
Publicado: (2020)

Proton pump inhibitor treatment is associated with acute-on-chronic liver failure in patients with advanced cirrhosis
por: Sturm, Lukas, et al.
Publicado: (2023)

Proton pump inhibitor treatment aggravates bacterial translocation in patients with advanced cirrhosis and portal hypertension
por: Sturm, Lukas, et al.
Publicado: (2023)

Barriers and Facilitators of Conducting Medication Reviews in Nursing Home Residents: A Qualitative Study
por: Wouters, Hans, et al.
Publicado: (2019)

Pharmacist clinical interventions in the ICU
por: Hunfeld, NG, et al.
Publicado: (2010)

Efficacy and pharmacokinetics of intravenous paracetamol in the critically ill patient
por: Samson, AD, et al.
Publicado: (2009)

Impact of aspirin on bleeding and blood product usage in off‐pump and on‐pump coronary artery bypass graft surgery
por: Little, Christopher, et al.
Publicado: (2022)

Screening for abnormal glycosylation in a cohort of adult liver disease patients
por: Jansen, Jos C., et al.
Publicado: (2020)

Root traits and belowground herbivores relate to plant–soil feedback variation among congeners
por: Wilschut, Rutger A., et al.
Publicado: (2019)

The immunogenetics of primary biliary cirrhosis: A comprehensive review
por: Webb, G.J., et al.
Publicado: (2015)

Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management
por: Cnossen, Wybrich R, et al.
Publicado: (2014)

Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis
por: Stadlbauer, Vanessa, et al.
Publicado: (2020)

Disappearance of Gastric Hyperplastic Polyps after the Discontinuation of Proton Pump Inhibitor in a Patient with Liver Cirrhosis
por: Yasugi, Kengo, et al.
Publicado: (2021)

Electroencephalography Signatures for Hepatic Encephalopathy in Cirrhosis Patients Treated with Proton Pump Inhibitors: An Exploratory Pilot Study
por: Zhang, Pan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tfic0juhr7f4k20askvmku4c3l